ProtoKinetix, Incorporated Stock Other OTC
Equities
PKTX
US7437221002
Biotechnology & Medical Research
Sales 2022 | - | Sales 2023 | - | Capitalization | 6.58M 9M |
---|---|---|---|---|---|
Net income 2022 | -1M -1.37M | Net income 2023 | - 0 | EV / Sales 2022 | - |
Net cash position 2022 | 25.55K 34.96K | Net cash position 2023 | 20.41K 27.92K | EV / Sales 2023 | - |
P/E ratio 2022 |
-4.29
x | P/E ratio 2023 |
-1.9
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 60.09% |
Managers | Title | Age | Since |
---|---|---|---|
Clarence Smith
CEO | Chief Executive Officer | 60 | 14-05-31 |
Michael Guzzetta
DFI | Director of Finance/CFO | 66 | 17-11-13 |
Victoria Bantz
LAW | General Counsel | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Clarence Smith
CEO | Chief Executive Officer | 60 | 14-05-31 |
Edward McDonough
BRD | Director/Board Member | 71 | 15-06-30 |
1st Jan change | Capi. | |
---|---|---|
+25.69% | 48.09B | |
+46.90% | 40.62B | |
-3.46% | 40.43B | |
-6.20% | 28.36B | |
+9.17% | 24.89B | |
-20.42% | 19.01B | |
+28.07% | 12.09B | |
+0.17% | 11.88B | |
-1.24% | 11.8B |